Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Amgen Inc. (AMGN), the drugmaker in pursuit of Onyx Pharmaceuticals Inc. (ONXX), boosted its offer for the company to $130 a share, according to a person familiar with the matter. The offer is currently the highest for Onyx, said the person, who asked not to be named because the process is private. Onyx disclosed in June that it was working with advisers to find a buyer after spurning an offer of $120 a share from Thousand Oaks, California-based Amgen. Onyx rejected Amgen’s proposal because management saw it as too low compared with other recent deals in the industry, a person familiar with the matter said at the time.
Help employers find you! Check out all the jobs and post your resume.
